GlobeNewswire: Novavax, Inc. Contains the last 10 of 360 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T21:23:55ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2021/03/08/2189100/0/en/Novavax-to-Participate-in-H-C-Wainwright-Virtual-Global-Life-Sciences-Conference-Fireside-Chat.html?f=22&fvtc=4&fvtv=12822Novavax to Participate in H.C. Wainwright Virtual Global Life Sciences Conference Fireside Chat2021-03-08T23:00:00Z<![CDATA[GAITHERSBURG, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat during the H.C. Wainwright Virtual Global Life Sciences conference. Novavax’ COVID-19 vaccine candidate, NVX-CoV2373, will be the topic of discussion.]]>https://www.globenewswire.com/news-release/2021/03/01/2184674/0/en/Novavax-Reports-Fourth-Quarter-and-Full-Year-2020-Financial-Results-and-Operational-Highlights.html?f=22&fvtc=4&fvtv=12822Novavax Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights2021-03-01T21:02:00Z<![CDATA[GAITHERSBURG, Md., March 01, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the fourth quarter and twelve months ended December 31, 2020.]]>https://www.globenewswire.com/news-release/2021/03/01/2184138/0/ja/%E3%83%8E%E3%83%B4%E3%82%A1%E3%83%B4%E3%82%A1%E3%83%83%E3%82%AF%E3%82%B9%E3%81%A8%E6%AD%A6%E7%94%B0%E3%81%8C%E3%83%8E%E3%83%B4%E3%82%A1%E3%83%B4%E3%82%A1%E3%83%83%E3%82%AF%E3%82%B9%E3%81%AECOVID-19%E3%83%AF%E3%82%AF%E3%83%81%E3%83%B3%E5%80%99%E8%A3%9C%E3%81%AE%E3%83%A9%E3%82%A4%E3%82%BB%E3%83%B3%E3%82%B9%E5%A5%91%E7%B4%84%E3%82%92%E7%A2%BA%E5%AE%9A%E3%81%97-%E6%AD%A6%E7%94%B0%E3%81%AF%E6%97%A5%E6%9C%AC%E3%81%A7%E7%AC%ACI-%E7%9B%B8%E8%A9%A6%E9%A8%93%E3%82%92%E9%96%8B%E5%A7%8B.html?f=22&fvtc=4&fvtv=12822ノヴァヴァックスと武田がノヴァヴァックスのCOVID-19ワクチン候補のライセンス契約を確定し、武田は日本で第I/Ⅱ相試験を開始2021-03-01T12:11:42Z<![CDATA[メリーランド州ゲイザースバーグ発, March 01, 2021 (GLOBE NEWSWIRE) -- 重症感染症の次世代ワクチンを開発するバイオテクノロジー企業ノヴァヴァックス (Novavax, Inc.) (Nasdaq: NVAX) は本日、8月に発表された武田薬品工業 (Takeda Pharmaceutical Company Limited) との協力関係の進展について発表した。両社は独占ライセンス契約を締結しており、武田はノヴァヴァックスのCOVID-19ワクチン候補であるNVX-CoV2373を日本で開発、製造、販売を行う。さらに、武田は第Ⅱ相試験でノヴァヴァックスのワクチン候補の投与を開始し、日本の被験者で免疫原性と安全性を試験していく。]]>https://www.globenewswire.com/news-release/2021/02/26/2183418/0/en/Novavax-and-Takeda-Finalize-License-Agreement-for-Novavax-COVID-19-Vaccine-Candidate-in-Japan-Takeda-Initiates-Phase-1-2-Trial-in-Japan.html?f=22&fvtc=4&fvtv=12822Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan2021-02-26T13:23:04Z<![CDATA[GAITHERSBURG, Md., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced progress in its collaboration with Takeda Pharmaceutical Company Limited, originally announced in August. The companies have signed an exclusive license agreement for Takeda’s development, manufacturing and commercialization of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate, in Japan. Additionally, Takeda dosed the first participants in a Phase 2 clinical trial to test the immunogenicity and safety of Novavax’ vaccine candidate in the Japanese population.]]>https://www.globenewswire.com/news-release/2021/02/22/2179402/0/en/Novavax-Completes-Enrollment-of-PREVENT-19-COVID-19-Vaccine-Pivotal-Phase-3-Trial-in-the-United-States-and-Mexico.html?f=22&fvtc=4&fvtv=12822Novavax Completes Enrollment of PREVENT-19, COVID-19 Vaccine Pivotal Phase 3 Trial in the United States and Mexico2021-02-22T12:00:00Z<![CDATA[GAITHERSBURG, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the complete enrollment of PREVENT-19, its pivotal Phase 3 study in the United States and Mexico to evaluate the efficacy, safety and immunogenicity of the company’s COVID-19 vaccine. Novavax has previously reported positive interim efficacy results of NVX-CoV2373, its recombinant protein-based vaccine candidate, in an ongoing Phase 3 clinical trial taking place in the United Kingdom.]]>https://www.globenewswire.com/news-release/2021/02/18/2178476/0/en/Novavax-Announces-Memorandum-of-Understanding-with-Gavi-for-Cumulative-Supply-to-COVAX-Facility-of-1-1-Billion-Doses-of-COVID-19-Vaccine.html?f=22&fvtc=4&fvtv=12822Novavax Announces Memorandum of Understanding with Gavi for Cumulative Supply to COVAX Facility of 1.1 Billion Doses of COVID-19 Vaccine2021-02-18T21:02:00Z<![CDATA[GAITHERSBURG, Md., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced a Memorandum of Understanding (MOU) with Gavi, the Vaccine Alliance (Gavi), to provide 1.1 billion cumulative doses of NVX-CoV2373, Novavax’ recombinant protein-based COVID-19 vaccine candidate, for the COVAX Facility. The vaccine doses will be manufactured and distributed globally by Novavax and Serum Institute of India (SII), the latter under an existing agreement between Gavi and SII. NVX-CoV2373 is being studied in two ongoing pivotal Phase 3 clinical trials: in the United States and Mexico, as well as in the United Kingdom (U.K.), for the prevention of COVID-19. Novavax has previously reported positive interim efficacy results from its U.K. trial.]]>https://www.globenewswire.com/news-release/2021/02/16/2176078/0/en/Novavax-to-Host-Conference-Call-to-Discuss-Fourth-Quarter-Financial-Results-and-Operational-Highlights-on-March-1-2021.html?f=22&fvtc=4&fvtv=12822Novavax to Host Conference Call to Discuss Fourth Quarter Financial Results and Operational Highlights on March 1, 20212021-02-16T13:00:00Z<![CDATA[GAITHERSBURG, Md., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its fourth quarter 2020 financial results and operational highlights following the close of U.S. financial markets on Monday, March 1, 2021.]]>https://www.globenewswire.com/news-release/2021/02/16/2175659/0/en/Novavax-Announces-Expanded-Collaboration-and-License-Agreement-with-SK-Bioscience-for-40-Million-Doses-of-COVID-19-Vaccine-for-South-Korea.html?f=22&fvtc=4&fvtv=12822Novavax Announces Expanded Collaboration and License Agreement with SK Bioscience for 40 Million Doses of COVID-19 Vaccine for South Korea2021-02-16T01:04:25Z<![CDATA[Existing partnership for manufacture of NVX-CoV2373 expanded to increase production capacity and supply vaccine to the Korean Government Existing partnership for manufacture of NVX-CoV2373 expanded to increase production capacity and supply vaccine to the Korean Government]]>https://www.globenewswire.com/news-release/2021/02/04/2170377/0/de/Novavax-und-die-Regierung-der-Schweiz-geben-eine-Grundsatzvereinbarung-zur-Bereitstellung-des-COVID-19-Impfstoffes-bekannt.html?f=22&fvtc=4&fvtv=12822Novavax und die Regierung der Schweiz geben eine Grundsatzvereinbarung zur Bereitstellung des COVID-19-Impfstoffes bekannt2021-02-04T22:05:26Z<![CDATA[Die Schweiz wird sechs Millionen Dosen des Impfstoffkandidaten NVX-CoV2373 von Novavax kaufen Die Schweiz wird sechs Millionen Dosen des Impfstoffkandidaten NVX-CoV2373 von Novavax kaufen]]>https://www.globenewswire.com/news-release/2021/02/04/2170335/0/en/Novavax-Announces-Start-of-Rolling-Review-by-Multiple-Regulatory-Authorities-for-COVID-19-Vaccine-Authorization.html?f=22&fvtc=4&fvtv=12822Novavax Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization2021-02-04T21:05:00Z<![CDATA[GAITHERSBURG, Md., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the start of the rolling review process for authorization of NVX-CoV2373, its COVID-19 vaccine, by multiple regulatory agencies. The reviews will continue while the company completes its pivotal Phase 3 trials in the United Kingdom (U.K.) and United States (U.S.) and through initial authorization for emergency use granted under country-specific regulations.]]>